Your browser is no longer supported. Please, upgrade your browser.
Settings
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E24.15 EPS (ttm)1.42 Insider Own0.10% Shs Outstand6.30B Perf Week-0.23%
Market Cap215.92B Forward P/E15.41 EPS next Y2.23 Insider Trans-7.29% Shs Float6.15B Perf Month-0.12%
Income9.09B PEG11.15 EPS next Q0.49 Inst Own73.90% Short Float2.80% Perf Quarter7.83%
Sales49.61B P/S4.35 EPS this Y-14.50% Inst Trans0.02% Short Ratio5.86 Perf Half Y16.15%
Book/sh11.32 P/B3.03 EPS next Y6.61% ROA6.70% Target Price36.28 Perf Year11.65%
Cash/sh5.74 P/C5.98 EPS next 5Y2.17% ROE15.10% 52W Range27.03 - 35.45 Perf YTD11.08%
Dividend1.12 P/FCF24.84 EPS past 5Y3.10% ROI8.90% 52W High-3.55% Beta0.80
Dividend %3.27% Quick Ratio2.40 Sales past 5Y0.10% Gross Margin80.80% 52W Low26.47% ATR0.55
Employees78300 Current Ratio2.70 Sales Q/Q-3.20% Oper. Margin29.20% RSI (14)51.67 Volatility1.74% 1.56%
OptionableYes Debt/Eq0.51 EPS Q/Q-50.00% Profit Margin23.10% Rel Volume0.69 Prev Close34.30
ShortableYes LT Debt/Eq0.44 EarningsJan 27 BMO Payout57.50% Avg Volume29.42M Price34.19
Recom2.20 SMA20-0.32% SMA501.90% SMA20012.14% Volume16,839,879 Change-0.32%
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Apr-15-13Reiterated Barclays Equal Weight $25 → $32
Jan-30-13Reiterated UBS Buy $29 → $31
Jan-30-13Reiterated Argus Buy $28 → $32
Jan-22-13Reiterated Barclays Equal Weight $24 → $25
Nov-27-12Downgrade MKM Partners Buy → Neutral $29 → $25
Oct-05-12Reiterated MKM Partners Buy $27 → $29
Nov-01-11Downgrade Standpoint Research Buy → Hold
Oct-07-11Initiated MKM Partners Buy $20.50
Sep-14-11Downgrade Barclays Capital Overweight → Equal Weight $21 → $19
Aug-10-11Upgrade Argus Hold → Buy $21
Aug-05-11Upgrade Standpoint Research Hold → Buy $21
Mar-14-11Downgrade Standpoint Research Buy → Hold
Nov-03-10Downgrade Argus Buy → Hold
May-21-10Initiated Jefferies Buy $17.80
Dec-16-09Initiated UBS Buy
Apr-27-09Initiated Standpoint Research Buy $20
Feb-12-09Upgrade Leerink Swann Mkt Perform → Outperform
Mar-26-15 01:36PM  FactSet: U.S. M&A Activity Dips in February as Private Equity Surges at Barrons.com
10:39AM  Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference at noodls
10:00AM  Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference Business Wire
09:47AM  Surge in R&D Spending Burnishes U.S. Image as Innovation Nation
08:06AM  Employers Boost Wellness Spending 17% From Yoga To Risk Assessments at Forbes
Mar-25-15 04:59PM  IPO Stock Watch: CAR-T Maker Cellectis Slips In Debut at Investor's Business Daily
04:57PM  Merger momentum keeps on rolling with Heinz deal for Kraft
03:45PM  Superconductor Technologies, Inc. (SCON), Pfizer Inc. (PFE), ACADIA Pharmaceuticals Inc. (ACAD): Sabby Capitals Latest Moves in Healthcare Sector at Insider Monkey
01:14PM  Science, patients driving rare disease drug research surge
12:00PM  Pfizer (PFE) Is The 'Chart of the Week' at TheStreet
11:10AM  4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
11:00AM  Lpath (LPTN) Crumbles on Failure of Kidney Cancer Drug Trial - Analyst Blog
07:20AM  The 5 Most Shorted NYSE Stocks in March at 24/7 Wall St.
Mar-24-15 03:33PM  Merck halts study in light of melanoma drugs success at Fortune
02:58PM  Hottest dividend stocks of 2015 at CNBC
11:02AM  Foreign investors buy UK firms at fastest pace since 2007 Reuters
11:01AM  Faster FDA Spurs Cancer Breakthroughs
10:50AM  Pfizer & Eli Lilly to Resume Phase III Study of Tanezumab - Analyst Blog
10:29AM  Will pharma rally continue?
10:21AM  Pfizer Invites Public To View And Listen To Webcast Of April 28 Conference Call With Analysts at noodls
10:00AM  Pfizer Invites Public To View And Listen To Webcast Of April 28 Conference Call With Analysts Business Wire
09:53AM  Stocks turn positive on strong housing number at CNBC
12:01AM  Faster FDA Spurs Cancer Breakthroughs as Drug Approvals Surge at Bloomberg
Mar-23-15 05:49PM  Chesapeake shares rise after capex budget trimmed at MarketWatch
05:01PM  Red flags for biotech
04:47PM  Pfizer Reveals Detailed Xeljanz Data from Psoriasis Study - Analyst Blog
04:45PM  Pfizer and ImmunoGen are big market movers
03:21PM  Eli Lilly (LLY) Stock Gains Today After FDA Lifts Ban on Pain Treatment Drug Trials at TheStreet
02:18PM  Halftime's hottest trades today: PFE, SPLS, BIIB, & UAL
02:14PM  Biogen downgrade, Pfizer rises
01:50PM  This surprising stock could hold the key to the Dow at CNBC
01:31PM  Blue Chips Outpace Broad Market; Sonic Breaks Out To New High at Investor's Business Daily
12:21PM  SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms
12:16PM  4 Stocks, 4 trades: Staples, Lululemon & more
12:07PM  Indexes Mixed In Light Trade; Pfizer, CyberArk Surge Higher at Investor's Business Daily
11:49AM  Pfizer Pushes Through Key Resistance Level
11:38AM  3 Biotech ETFs in Focus as Biogen Soars - ETF News And Commentary
10:48AM  Pfizer, Lilly to resume study testing pain drug Reuters
10:38AM  Pfizer's stock jumps to near 11-year high at MarketWatch
10:22AM  Stocks trade near highs; dollar, oil eyed at CNBC
09:36AM  Jefferies Raises Pfizer PT, Says Company Has Multiple Ways To Win
09:08AM  Pfizer, Lilly to Resume Studies of Pain Treatment Tanezumab at The Wall Street Journal
09:04AM  Big Pharma But Not Such Big Money at Forbes
08:25AM  Wall Street uneasy ahead of busy data week at CNBC
08:17AM  Pfizer, Lilly to resume late-stage study testing pain drug Reuters
08:16AM  Early movers: Biogen, Staples, Pfizer & more at CNBC
08:00AM  Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab Business Wire
Mar-22-15 09:00AM  Employers Warm To Obamacare, Stick With Coverage at Forbes
Mar-20-15 02:10PM  Pfizer Announces Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 Psoriasis Trials at noodls
01:00PM  Pfizer Announces Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 Psoriasis Trials Business Wire
11:58AM  The PharmacyclicsAbbVie Merger Shareholders Could Benefit
07:25AM  AstraZeneca Lags in Cancer Race
07:25AM  AstraZeneca Lags in Cancer Race Where Losing May Spur Buyout at Bloomberg
Mar-19-15 06:15PM  Esperion Therapeutics' fight against bad cholesterol
04:10PM  Pfizer Announces Publication of CAPiTA Data on Prevenar 13 - Analyst Blog
03:12PM  The Marijuana CARERS Act: What You Need To Know
01:51PM  Will The Strong Dollar Scratch Tiffany's Shine? at Investor's Business Daily
12:55PM  Moment of truth for Biogen's big Alzheimer's bet at CNBC
10:06AM  Stocks need clarity on the tightening cycle at CNBC
09:03AM  Davidson Kempner Trades Key Positions During 4Q14
08:12AM  The charity that matches surplus medicine with acute need at Financial Times
Mar-18-15 09:05PM  Understanding Johnson & Johnsons Ownership Structure
08:22PM  Hot Biotech Juno Therapeutics Burning Through Cash at Investor's Business Daily
06:45PM  Study: Prevnar vaccine slashed serious infections in elderly AP
05:36PM  Results of Pfizers Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Published in the New England Journal of Medicine at noodls
05:05PM  Where Does Johnson & Johnson Stand in the Industry?
05:04PM  Results of Pfizers Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Published in the New England Journal of Medicine Business Wire
12:30PM  Veeva Picked as CRM Partner by GlaxoSmithKline, Stock Up - Analyst Blog
11:05AM  What Risks Does Johnson & Johnson Face?
10:39AM  Help Protect Texas' Babies: Make sure your children are fully vaccinated PR Newswire
Mar-17-15 06:12PM  Cramer: These trends are wreaking havoc right now at CNBC
04:41PM  Apple still buyback king as repurchases overall slow down at MarketWatch
04:09PM  San Diego sues Monsanto over PCB pollution at bizjournals.com
01:55PM  Hey Big Spender: Apple Is Tops In Q4 Buyback Activity at Forbes
10:51AM  Why These ETFs are the Best Way to Trade Pfizer at Investopedia
08:35AM  6 Stocks Will See Massive Buying and Selling on S&P Quarterly Rebalance at 24/7 Wall St.
04:00AM  Dementia drug research aided by $100 mln venture capital fund
02:05AM  Johnson & Johnsons Gross Margin Increased
Mar-16-15 06:00PM  Making Money With Charles Payne: 03/16/15 at Fox Business
05:05PM  The Salix-Endo Proposal: Basics of the Transaction
04:06PM  How Much Upside Is There in the MacerichSimon Property Deal?
04:06PM  Background on Simon Property Group
04:06PM  Rationale for the MacerichSimon Property Transaction
04:06PM  The MacerichSimon Property Deal: Hostile or friendly?
04:05PM  The FreescaleNXP Merger: Freescale at a glance
03:17PM  Amgen, other drug company shares jump on cholesterol drug findings at MarketWatch
03:01PM  Amgen: Looking for a Wild Card at Barrons.com
11:05AM  Johnson & Johnsons Revenue Stream Increased in 2014
07:27AM  5 Rocket Stocks to Buy in March for Blastoff Gains at TheStreet
12:11AM  MoneyBeat: U.S. Catches M&A Fever at The Wall Street Journal
12:10AM  [$$] New Cholesterol-Lowering Drugs May Cut Heart-Attack Risk at The Wall Street Journal
Mar-15-15 09:07PM  MoneyBeat: U.S. Catches M&A Fever at The Wall Street Journal
11:00AM  Experimental cholesterol drugs cut heart risk, but questions remain
Mar-13-15 10:56PM  12 Great Dividend Stocks at Barrons.com
07:23PM  Dollar Surge Weighs on Dow
04:00PM  Stocks close lower, with Dow off triple digits on dollar surge at CNBC
03:33PM  These cholesterol drugs stocks are poised to move at CNBC
03:06PM  The Next Steps in the Salix-Endo Proposal
10:26AM  Patient Empowerment: The Secret Sauce Behind 23andMe's Pipeline-In-A-Database Strategy at Forbes
08:46AM  These new meds could move stocks
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women's/men's health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUSMAN SALLYExecutive Vice PresidentMar 12Sale34.0046,1791,570,086150,899Mar 13 10:39 AM
Dolsten MikaelPresident R&DMar 05Sale34.4658,2982,009,152355,911Mar 06 07:32 PM
READ IAN CChairman & CEOMar 05Sale34.6267,5002,336,7931,408,457Mar 06 07:19 PM
OLSON LAURIE JExecutive Vice PresidentFeb 25Option Exercise17.6921,115373,52481,240Feb 27 06:49 PM
HILL CHARLES HExecutive Vice PresidentFeb 25Option Exercise17.6922,523398,432121,572Feb 27 06:42 PM
JOHNSON RADY AExecutive Vice PresidentFeb 25Option Exercise17.6919,426343,64656,250Feb 27 06:42 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 25Option Exercise17.6932,855581,205141,441Feb 27 06:42 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 25Option Exercise17.69101,3511,792,899227,982Feb 27 06:42 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 25Option Exercise17.6923,649418,35188,933Feb 27 06:42 PM
READ IAN CChairman & CEOFeb 25Option Exercise17.69197,0723,486,2041,568,718Feb 27 06:50 PM
SUSMAN SALLYExecutive Vice PresidentFeb 25Option Exercise17.6995,7211,693,304261,233Feb 27 06:56 PM
YOUNG JOHN DGroup PresidentFeb 25Option Exercise17.6949,364873,249159,673Feb 27 06:56 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Option Exercise26.20104,0002,724,800288,775Feb 17 05:50 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Sale34.73104,0003,612,323184,775Feb 17 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 12Sale34.859,000313,66170,252Feb 13 01:50 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.3014,800507,619440,886Feb 12 04:01 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.2380,2002,744,861360,686Feb 12 04:01 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 10Sale33.789,000304,02079,252Feb 11 08:02 PM
LANKLER DOUGLAS MExecutive Vice PresidentDec 31Option Exercise18.1921,413389,502127,673Jan 05 05:17 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerDec 31Option Exercise18.1932,120584,263207,985Jan 05 05:17 PM
HILL CHARLES HExecutive Vice PresidentDec 31Option Exercise18.1926,767486,892126,245Jan 05 05:17 PM
OLSON LAURIE JExecutive Vice PresidentDec 31Option Exercise18.1918,737340,82675,811Jan 05 05:17 PM
YOUNG JOHN DGroup PresidentDec 31Option Exercise18.1926,767486,892128,860Jan 05 05:17 PM
JOHNSON RADY AExecutive Vice PresidentDec 31Option Exercise18.1932,120584,26361,803Jan 05 05:16 PM
MADDALUNA ANTHONY JExecutive Vice PresidentDec 31Option Exercise18.1926,767486,892107,900Jan 05 05:16 PM
BOURLA ALBERTGroup PresidentDec 31Option Exercise18.1916,060292,131113,177Jan 05 05:16 PM
MADDALUNA ANTHONY JExecutive Vice PresidentDec 08Sale32.006,500208,00082,830Dec 09 10:44 AM
HILL CHARLES HExecutive Vice PresidentNov 10Sale30.188,285250,04199,478Nov 10 05:34 PM
YOUNG JOHN DGroup PresidentNov 07Option Exercise26.2021,600565,920123,462Nov 10 05:34 PM
DAMELIO FRANK AExecutive Vice PresidentNov 07Sale29.7807454,687Nov 10 05:34 PM
YOUNG JOHN DGroup PresidentNov 07Sale29.8921,600645,548101,862Nov 10 05:34 PM
READ IAN CChairman & CEOOct 30Option Exercise17.0354,585929,5831,465,906Nov 03 06:23 PM
DAMELIO FRANK AExecutive Vice PresidentOct 30Option Exercise17.0365,5021,115,499501,494Nov 03 06:23 PM
READ IAN CChairman & CEOOct 30Sale29.7667,5002,008,8001,358,862Nov 03 06:23 PM
MADDALUNA ANTHONY JExecutive Vice PresidentOct 29Sale29.562,42571,68388,987Oct 30 06:23 PM
OLSON LAURIE JExecutive Vice PresidentJun 12Option Exercise26.2036,275950,40593,010Jun 13 12:29 PM
OLSON LAURIE JExecutive Vice PresidentJun 12Sale29.5336,2751,071,27856,735Jun 13 12:29 PM